Quantitative assessment of miR34a as an independent prognostic marker in breast cancer

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 61-68

  Agarwal, Seema ^a,c   Hanna, J ^a,d   Sherman, M E ^b   Figueroa, J ^b   Rimm, D L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

breast cancer; miR34a; qISH

Indexed keywords

MICRORNA 34A; MICRORNA; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TISSUE MICROARRAY; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MICRORNAS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84920651033     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.573     Document Type: Article

References (44)

1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2): 281-297.
2. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17(15): 1298-1307.
3. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11): 1323-1327.
4. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21): 7252-7259.
5. Chen F, Hu SJ (2012) Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 26(2): 79-86.
6. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA (2010) microRNAs in cancer: from bench to bedside. Adv Cancer Res 108: 113-157.
7. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10): 704-714.
8. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1): 92-105.
9. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M (2009) miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30(11): 1903-1909.
10. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med 60: 167-179.
11. Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L (2012) microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-beta signaling in glioblastoma. Cancer Discov 2(8): 736-749.
12. Giltnane JM, Moeder CB, Camp RL, Rimm DL (2009) Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 115(11): 2400-2409.
13. Giltnane JM, Rimm DL (2004) Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract 1(2): 104-111.
14. Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL (2012) Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. BioTechniques 52(4): 235-245.
15. Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, Hewitt SM, Conway CM, Lissowska J, Brinton LA, Prokunina-Olsson L, Dawson SJ, Caldas C, Easton DF, Chanock SJ, Figueroa JD (2014) Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat 143(1): 181-187.
16. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18(2): 534-545.
17. Javeri A, Ghaffarpour M, Taha MF, Houshmand M (2013) Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol 30(1): 413.
18. Kaklamani V (2006) A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert Rev Mol Diagn 6(6): 803-809.
19. Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H (2011) Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 10(8): M111 010462.
20. Kasinski AL, Slack FJ (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11(12): 849-864.
21. Kasinski AL, Slack FJ (2012) miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72(21): 5576-5587.
22. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6(5): 376-385.
23. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P (2012) Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 7(5): e37601.
24. Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4: 199-227.
25. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1): 15-20.
26. Li L, Xie X, Luo J, Liu M, Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Wei W, Yang M, Hung MC (2012) Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther 20(12): 2326-2334.
27. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X (2013) MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 13(2): 109-117.
28. Li XJ, Ren ZJ, Tang JH (2014) MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis 5: e1327.
29. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2): 211-215.
30. Luo D, Wilson JM, Harvel N, Liu J, Pei L, Huang S, Hawthorn L, Shi H (2013) A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med 11: 57.
31. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ (2011) Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130(2): 663-679.
32. Moeder CB, Giltnane JM, Moulis SP, Rimm DL (2009) Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol (Clifton, NJ) 520: 163-175.
33. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A (2011) MicroRNAs can generate thresholds in target gene expression. Nat Genet 43(9): 854-859.
34. Nuovo GJ (2010) In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. Methods (San Diego, Calif) 52(4): 307-315.
35. Pena JT, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, Mihailovic A, Lim C, Holoch D, Berninger P, Zavolan M, Tuschl T (2009) miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 6(2): 139-141.
36. Pencheva N, Tavazoie SF (2013) Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 15(6): 546-554.
37. Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Aittomaki K, Heikkila P, Bartek J, Blomqvist C, Butzow R, Nevanlinna H (2011) MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One 6(11): e26122.
38. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A (2011a) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10(8): 1470-1480.
39. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A (2011b) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10(8): 1470-1480.
40. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26(34): 5017-5022.
41. Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL (2011) Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 29(22): 2978-2984.
42. Yang F, Li QJ, Gong ZB, Zhou L, You N, Wang S, Li XL, Li JJ, An JZ, Wang DS, He Y, Dou KF (2013a) MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 13(1): 77-86.
43. Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X, Liu Z (2013b) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32(36): 4294-4303.
44. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C (2009) MicroRNA profiling of human gastric cancer. Mol Med Rep 2(6): 963-970.